home / stock / amgn / amgn quote
$249.51 Last:
-0.88% Change Percent:
$249.07 Open:
$251.72 Previous Close:
$250.67 High:
$247.88 Low:
876,613 Volume:
12/31/1969 07:00:00 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Stock Date | Open Price | Close Price | High | Low | Volume |
---|---|---|---|---|---|
2022-08-15 | 249.07 | 251.72 | 250.67 | 247.88 | 876,613 |
2022-08-12 | 248.52 | 251.72 | 249.85 | 246.3 | 3,460,883 |
2022-08-11 | 252.04 | 251.72 | 253.36 | 247.99 | 2,686,696 |
2022-08-10 | 249.81 | 251.72 | 252.46 | 248.53 | 2,628,294 |
2022-08-09 | 247.21 | 251.72 | 249.72 | 247.21 | 2,061,749 |
2022-08-08 | 245 | 251.72 | 247.74 | 244.31 | 2,783,783 |
2022-08-05 | 246.46 | 251.72 | 247.08 | 241.79 | 2,723,408 |
2022-08-04 | 247 | 251.72 | 249 | 246.2 | 2,647,024 |
2022-08-03 | 245.94 | 251.72 | 249.33 | 245.18 | 2,061,298 |
2022-08-02 | 246.69 | 251.72 | 247.85 | 243.78 | 2,292,255 |
2022-08-01 | 247.34 | 251.72 | 248.16 | 244.651 | 1,957,021 |
2022-07-29 | 248.46 | 251.72 | 249.57 | 245.74 | 3,295,633 |
2022-07-28 | 251.72 | 251.72 | 251.72 | 245.725 | 2,158,756 |
2022-07-26 | 249.63 | 249.63 | 253.07 | 248.75 | 987,714 |
2022-07-25 | 246.86 | 248.72 | 249.0937 | 246.56 | 1,771,131 |
2022-07-19 | 246.96 | 247.32 | 247.775 | 245.04 | 3,373,901 |
2022-07-18 | 248.55 | 243.84 | 249.45 | 242.92 | 2,231,381 |
2022-07-15 | 247.39 | 248.69 | 249.13 | 245.441 | 2,805,358 |
2022-07-14 | 245.02 | 245.59 | 246.82 | 242.95 | 2,885,765 |
2022-07-13 | 246.37 | 247.09 | 248.75 | 245.1601 | 2,498,009 |
News, Short Squeeze, Breakout and More Instantly...
AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022 PR Newswire Phase 1 Tarlatamab Study Showed Encouraging Antitumor Activity With Median Duration of Response of 13 Months in Small Cell Lung Cancer No Approved Treatment Options Available to Patients in Th...
AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS PR Newswire First Data From LUMAKRAS Plus Immunotherapy and LUMAKRAS Plus SHP2 Inhibitor Combinations Show Clinical Activity and Su...
AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif. , Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2022. Key results include: Total revenues increased ...